CaCCinh-A01

CaCCinh-A01 is a potent, small-molecule inhibitor of calcium-activated chloride channels (CaCCs), with high specificity for Anoctamin-1 (ANO1/TMEM16A). Identified through high-throughput screening by researchers at the University of California, San Francisco, it serves as a critical pharmacological tool for investigating the role of chloride transport in various physiological and pathological processes. In oncology research, CaCCinh-A01 has been shown to inhibit the proliferation, migration, and invasion of cancer cells, such as the HT-29 colorectal line, by inducing cell cycle arrest and apoptosis. Additionally, it is studied for its potential to reduce airway mucus hypersecretion in respiratory diseases like asthma and cystic fibrosis, as well as for its effects on smooth muscle contraction and fluid secretion in the gastrointestinal tract.

Other names

6-t-butyl-2-(furan-2-carboxamido)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylic acid